Tags

Type your tag names separated by a space and hit enter

The effect of inhalation of the leukotriene receptor antagonist, SK&F 104353, on leukotriene C4- and leukotriene E4-induced bronchoconstriction in subjects with asthma.
J Allergy Clin Immunol. 1991 Aug; 88(2):193-8.JA

Abstract

The effect of prior inhalation of the sulfidopeptide leukotriene receptor antagonist, SK&F 104353 (963 +/- 43.7 micrograms; mean +/- SEM), on (LTC4)- and leukotriene E4 (LTE4)-induced bronchoconstriction has been studied in six subjects with asthma (six male subjects, aged 24 to 36 years). Inhalation challenges with either synthetic LTC4 or LTE4 were performed after prior inhalation of aerosolized SK&F 104353 or placebo in a double-blind, randomized fashion. Airway responsiveness to each agonist was determined by the cumulative dose of agonist required to induce a 35% fall in specific airway conductance (PD35) as determined by linear interpolation of the log dose-response curve. There was no change in baseline specific airway conductance after inhalation of either placebo or SK&F 104353. LTC4- and LTE4-induced bronchoconstrictions were significantly inhibited by aerosolized inhalation of SK&F 104353 30 minutes before challenge. The geometric mean (GM) PD35 of LTC4 on the open-therapy and placebo-therapy days was 0.043 nmol (range, 0.01 to 0.1 nmol) and 0.036 nmol (range, 0.01 to 0.1 nmol), respectively. On the treatment day with SK&F 104353, it was not possible to obtain a GM PD35 LTC4 up to a maximum concentration of 0.52 nmol LTC4 (p less than 0.01). The GM PD35 of LTE4 on the open-therapy and placebo-therapy days was 0.30 nmol (range, 0.13 to 0.76 nmol) and 0.39 nmol (range, 0.14 to 0.9 nmol), respectively. On the treatment day with SK&F 104353, it was not possible to obtain a GM PD35 LTE4 up to a maximum concentration of 5 nmol LTE4 (p less than 0.005). Thus, LTC4- and LTE4-induced bronchoconstrictions are both inhibited by SK&F 104353.

Authors+Show Affiliations

Department of Allergy and Allied Respiratory Disorders, United Medical School, Guy's Hospital, London, England.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1652604

Citation

Christie, P E., et al. "The Effect of Inhalation of the Leukotriene Receptor Antagonist, SK&F 104353, On Leukotriene C4- and Leukotriene E4-induced Bronchoconstriction in Subjects With Asthma." The Journal of Allergy and Clinical Immunology, vol. 88, no. 2, 1991, pp. 193-8.
Christie PE, Spur BW, Lee TH. The effect of inhalation of the leukotriene receptor antagonist, SK&F 104353, on leukotriene C4- and leukotriene E4-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 1991;88(2):193-8.
Christie, P. E., Spur, B. W., & Lee, T. H. (1991). The effect of inhalation of the leukotriene receptor antagonist, SK&F 104353, on leukotriene C4- and leukotriene E4-induced bronchoconstriction in subjects with asthma. The Journal of Allergy and Clinical Immunology, 88(2), 193-8.
Christie PE, Spur BW, Lee TH. The Effect of Inhalation of the Leukotriene Receptor Antagonist, SK&F 104353, On Leukotriene C4- and Leukotriene E4-induced Bronchoconstriction in Subjects With Asthma. J Allergy Clin Immunol. 1991;88(2):193-8. PubMed PMID: 1652604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of inhalation of the leukotriene receptor antagonist, SK&F 104353, on leukotriene C4- and leukotriene E4-induced bronchoconstriction in subjects with asthma. AU - Christie,P E, AU - Spur,B W, AU - Lee,T H, PY - 1991/8/1/pubmed PY - 1991/8/1/medline PY - 1991/8/1/entrez SP - 193 EP - 8 JF - The Journal of allergy and clinical immunology JO - J Allergy Clin Immunol VL - 88 IS - 2 N2 - The effect of prior inhalation of the sulfidopeptide leukotriene receptor antagonist, SK&F 104353 (963 +/- 43.7 micrograms; mean +/- SEM), on (LTC4)- and leukotriene E4 (LTE4)-induced bronchoconstriction has been studied in six subjects with asthma (six male subjects, aged 24 to 36 years). Inhalation challenges with either synthetic LTC4 or LTE4 were performed after prior inhalation of aerosolized SK&F 104353 or placebo in a double-blind, randomized fashion. Airway responsiveness to each agonist was determined by the cumulative dose of agonist required to induce a 35% fall in specific airway conductance (PD35) as determined by linear interpolation of the log dose-response curve. There was no change in baseline specific airway conductance after inhalation of either placebo or SK&F 104353. LTC4- and LTE4-induced bronchoconstrictions were significantly inhibited by aerosolized inhalation of SK&F 104353 30 minutes before challenge. The geometric mean (GM) PD35 of LTC4 on the open-therapy and placebo-therapy days was 0.043 nmol (range, 0.01 to 0.1 nmol) and 0.036 nmol (range, 0.01 to 0.1 nmol), respectively. On the treatment day with SK&F 104353, it was not possible to obtain a GM PD35 LTC4 up to a maximum concentration of 0.52 nmol LTC4 (p less than 0.01). The GM PD35 of LTE4 on the open-therapy and placebo-therapy days was 0.30 nmol (range, 0.13 to 0.76 nmol) and 0.39 nmol (range, 0.14 to 0.9 nmol), respectively. On the treatment day with SK&F 104353, it was not possible to obtain a GM PD35 LTE4 up to a maximum concentration of 5 nmol LTE4 (p less than 0.005). Thus, LTC4- and LTE4-induced bronchoconstrictions are both inhibited by SK&F 104353. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/1652604/The_effect_of_inhalation_of_the_leukotriene_receptor_antagonist_SK&F_104353_on_leukotriene_C4__and_leukotriene_E4_induced_bronchoconstriction_in_subjects_with_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0091-6749(91)90328-L DB - PRIME DP - Unbound Medicine ER -